DFTX- Definium Therapeutics, Inc.

Trade Summary

1 week ago, Barrow Robert, serving as Chief Executive Officer at Definium Therapeutics, Inc. (DFTX), sold 19,023 shares at $37.94 per share, for a total transaction value of $721,732.62. Following this transaction, Barrow Robert now holds 1,494,640 shares of DFTX.

This sale represents a 1.26% decrease in Barrow Robert's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, September 3, 2026 and publicly disclosed via SEC Form 4 filing on Friday, September 4, 2026 at 9:30 PM ET, 1 day after the trade was made.

Definium Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.